AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
DURHAM, N.C., Sept. 20, 2017 -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at the 2017 Leerink Partners Rare Disease Roundtable Series on Wednesday, September 27, 2017 at 9:30 a.m. EDT in New York City.
A live audio webcast of the event will be available via the "Investor Relations" page of the Dova website, www.dova.com. Please log on through Dova's website approximately 10 minutes before the scheduled start time. A replay of the webcast will be archived on Dova's website for 90 days following the call.
About Dova Pharmaceuticals, Inc.
Dova is a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, with an initial focus on addressing thrombocytopenia. Dova’s lead drug candidate, avatrombopag, has successfully completed two pivotal Phase 3 clinical trials for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo a procedure.
Contacts
Doug Blankenship
(919) 748-5975
[email protected]
Westwicke Partners
John Woolford
(443) 213-0506
[email protected]
